IPSC on Nasdaq

Century Therapeutics (United States)

We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2018Founded1

Compare with ImmunityBio, Inc., Agenus or Sutro Biopharma, or pick any stock.

  • TickerIPSC on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPhiladelphia, Pennsylvania1
  • Websitewww.centurytx.com
  • Incorporated inDE3
  • Business address25 N 38Th Street, 12Th Floor, Philadelphia, Pa3
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. As a result, we believe such “off-the-shelf" therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population. What we believe further sets us apart from other allogeneic approaches is our focus on induced pluripotent stem cells, or iPSCs, which possess the unique ability to self-renew …4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-15.8%Operating margin5
-8.8%Net margin5
1556.8%Revenue growth, 20255
-6.0%Return on equity5
-$104.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢$109.1M
  • Income tax0¢$68.0K

Out of $109.2M in revenue.5 The company lost money this year.

Financial statements

Revenue675$109.2M in 2025+2000% since 2022
0$50.0M$100.0M$150.0M2022: $5.2M$5.2M20222023: $2.2M$2.2M2023−57%2024: $6.6M$6.6M2024+195%2025: $109.2M$109.2M2025+1557%
Operating income89675-$17.3M in 2025−68% since 2020
-$150.0M-$100.0M-$50.0M02020: -$53.9M-$53.9M20202021: -$94.9M-$94.9M2021+76%2022: -$133.8M-$133.8M2022+41%2023: -$146.5M-$146.5M2023+10%2024: -$138.1M-$138.1M2024−6%2025: -$17.3M-$17.3M2025−87%
Net income89675-$9.6M in 2025−82% since 2020
-$150.0M-$100.0M-$50.0M02020: -$53.6M-$53.6M20202021: -$95.8M-$95.8M2021+79%2022: -$130.9M-$130.9M2022+37%2023: -$136.7M-$136.7M2023+4%2024: -$126.6M-$126.6M2024−7%2025: -$9.6M-$9.6M2025−92%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Collaboration revenue$109.2M$6.6M
Research and development$95.7M$107.2M
General and administrative$24.0M$33.2M
Impairment of long-lived assets$6.8M
Impairment of goodwill$4.3M
Total operating expenses$126.4M$144.7M
Loss from operations-$17.3M-$138.1M
Interest income$7.3M$13.0M
Other income$275.0K$354.0K
Total other income$7.6M$13.4M
Loss before provision for income taxes-$9.6M-$124.8M
(Benefit) provision for income taxes-$68.0K$1.8M
Net loss-$9.6M-$126.6M
Net loss per common share Basic (in dollars per share)-$0.14-$1.61
Net loss per common share Diluted (in dollars per share)-$0.14-$1.61
Weighted average common shares outstanding Basic (in shares)86.6M shares78.6M shares
Weighted average common shares outstanding Diluted (in shares)86.6M shares78.6M shares
Unrealized gain (loss) on investments-$294.0K$153.0K
Foreign currency translation gain$63.0K
Comprehensive loss-$9.9M-$126.3M

Compare Century Therapeutics (United States) with another company

Leadership

Who has led Century Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Osvaldo Flores2021–2023
  2. Brent Pfeiffenberger2023–now

President

  1. Hyam Levitsky2021–2024
  2. Brent Pfeiffenberger2023–now

Chief financial officer

  1. Michael Craig Diem2023
  2. Morgan Conn2024
20202025
Board members and other officers (20)

Timeline

  1. Dec 6, 2023New chief executive Brent Pfeiffenberger becomes CEO12
  2. Jun 17, 2021New chief executive Osvaldo Flores becomes CEO13
  3. 2018Founded Founded1

Filings

388 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 74 major events, 161 insider forms, 32 large holders, 101 other. The latest 20:

  1. Oct 2, 20268-K EDGAR
  2. Sep 15, 20264 EDGAR
  3. Sep 15, 20264 EDGAR
  4. Sep 15, 20264 EDGAR
  5. Sep 14, 2026144 EDGAR
  6. Sep 14, 2026144 EDGAR
  7. Sep 10, 20264 EDGAR
  8. Sep 10, 20263 EDGAR
  9. Sep 9, 20264 EDGAR
  10. Sep 9, 20264 EDGAR
  11. Sep 9, 20264 EDGAR
  12. Sep 9, 20268-K EDGAR
  13. Sep 8, 2026144 EDGAR
  14. Aug 18, 20264 EDGAR
  15. Aug 12, 20268-K EDGAR
  16. Aug 12, 202610-Q EDGAR
  17. Aug 5, 20264 EDGAR
  18. Jun 16, 20268-K EDGAR
  19. Jun 15, 20264 EDGAR
  20. Jun 15, 20264 EDGAR

The 388 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

67 open-market trades by officers, directors and large owners since October 2021: 4 buys and 63 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2026Russotti GregorySee RemarksSale2,587$1.93$5.0KForm 4
Sep 14, 2026Carr DouglasSVP Finance & OperationsSale1,658$1.93$3.2KForm 4
Sep 8, 2026Russotti GregorySee RemarksSale534$2.05$1.1KForm 4
Sep 8, 2026Carr DouglasSVP Finance & OperationsSale254$2.05$521Form 4
Aug 3, 2026Carr DouglasSVP Finance & OperationsSale275$1.98$544Form 4
Jun 12, 2026Russotti GregorySee RemarksSale2,584$2.23$5.8KForm 4
Jun 12, 2026Carr DouglasSVP Finance & OperationsSale1,654$2.23$3.7KForm 4
Jun 8, 2026Russotti GregorySee RemarksSale524$2.11$1.1KForm 4
Jun 8, 2026Carr DouglasSVP Finance & OperationsSale249$2.11$525Form 4
May 4, 2026Carr DouglasSVP Finance & OperationsSale264$2.34$618Form 4
Mar 12, 2026Russotti GregorySee RemarksSale10,076$2.55$25.7KForm 4
Mar 12, 2026Carr DouglasSVP Finance & OperationsSale7,043$2.55$18.0KForm 4
Mar 9, 2026Russotti GregorySee RemarksSale479$2.54$1.2KForm 4
Mar 9, 2026Carr DouglasSVP Finance & OperationsSale247$2.54$627Form 4
Feb 3, 2026Carr DouglasSVP Finance & OperationsSale323$1.82$588Form 4
Dec 22, 2025Cowan ChadChief Scientific OfficerBuy58,060$0.85$49.4KForm 4
Dec 12, 2025Pfeiffenberger BrentPresident and CEOBuy52,000$0.58$30.2KForm 4
Dec 8, 2025Russotti GregorySee RemarksSale526$0.53$279Form 4
Dec 8, 2025Carr DouglasSVP Finance & OperationsSale257$0.53$136Form 4
Nov 20, 2025Cowan ChadChief Scientific OfficerSale5,462$0.50$2.7KForm 4

All 67 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 98. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.17,754,430$43.5M0.4%No change
TCG Crossover Management, LLC17,754,430$43.4M1.0%No change
Versant Venture Management, LLC12,166,109$29.8M18.3%No change
Deep Track Capital, LP9,462,645$23.2M0.3%−25,100
Rtw Investments, LP8,695,652$21.3M0.2%No change
Venrock Adviser, LLC8,695,652$21.3M0.6%No change
Commodore Capital LP8,695,652$21.3M1.3%No change
BlackRock, Inc.8,091,768$19.8M0.0%+6,567,346
Vanguard Capital Management LLC5,703,680$14.0M0.0%+17,476
Balyasny Asset Management L.P.5,522,944$13.5M0.0%+505,211
Point72 Asset Management, L.P.4,980,526$12.2M0.0%−984,152
Seven Fleet Capital Management LP4,347,826$10.7M1.8%+1,400,000
Woodline Partners LP4,257,530$10.4M0.0%+1,214,052
Millennium Management LLC4,194,981$10.3M0.0%−472,082
Trails Edge Capital Partners, LP4,134,969$10.1M1.6%+1,684,976
Spruce Street Capital LP4,059,054$9.9M2.0%No change
Adage Capital Partners Gp, L.l.c.3,789,538$9.3M0.0%No change
Geode Capital Management, LLC2,979,529$7.3M0.0%+1,677,865
Two Sigma Investments, LP2,699,013$6.6M0.0%+327,583
DAFNA Capital Management LLC2,400,458$5.9M1.1%−33,895
Stempoint Capital LP2,146,182$5.3M0.9%New
State Street Corp1,843,154$4.5M0.0%+1,456,431
Northern Trust Corp1,593,944$3.9M0.0%+1,363,124
DV Trading LLC1,400,000$3.4M0.3%No change
Rock Springs Capital Management LP1,304,347$3.2M0.2%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49